Navigation Links
Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
Date:5/22/2012

WASHINGTON, May 22, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, announced today that the Company presented two posters at the Society for Research on Biological Rhythms (SRBR) annual meeting in Destin, Florida.

The first poster entitled Pleiomorphic Expression of Non-24-Hour Disorder in the Totally Blind, provides insight into the challenges faced by individuals suffering with this circadian rhythm disorder based on screening data collected during the Safety and Efficacy of Tasimelteon (SET) trial.  The second poster, Diurnal Oscillations of Plasma Metabolic Profiles From Individual Human Participants Under Usual Sleep-Wake Conditions, suggests a large number of metabolites have significant diurnal rhythms under usual sleep-wake and feeding conditions in healthy subjects. 

ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders. For more on Vanda, please visit http://www.vandapharma.com/.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the extent and effectiveness of the development, sales and marketing and distribution support Fanapt® receives; Vanda's ability to successfully commercialize Fanapt® outside of the U.S. and Canada; delays in the completion of Vanda's clinical trials; a failure of Vanda's products, product candidates or partnered products to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products, product candidates or partnered products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's products, product candidates or partnered products in the marketplace, or a failure to become or remain profitable; Vanda's expectations regarding trends with respect to its costs and expenses; Vanda's inability to obtain the capital necessary to fund additional research and development activities; Vanda's failure to identify or obtain rights to new products or product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; limitations on Vanda's ability to utilize some or all of its prior net operating losses and research and development credits; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products or product candidates under its license and sublicense agreements and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2011 which is on file with the SEC and available on the SEC's website at http://www.sec.gov/. In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

COMPANY CONTACT: 
Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc.
(202) 734-3414
cristina.murphy@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
2. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
3. Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
4. Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel
5. Vanda Pharmaceuticals Reports Third Quarter 2011 Results
6. Vanda Pharmaceuticals Appoints Chief Commercial Officer
7. Vanda Pharmaceuticals to Participate in UBS Global Life Sciences Conference
8. Vanda Pharmaceuticals to Participate in Stifel Nicolaus Global Healthcare Conference and Jefferies Fall 2011 Mid-Atlantic Corporate Access Day
9. Vanda Pharmaceuticals Reports Second Quarter 2011 Results
10. Vanda Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
11. Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Probiomed S.A. de C.V. for Commercialization of Fanapt™ in Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Germany Cataract Surgery Devices Market Outlook ... Cataract Surgery Devices Market Outlook to 2022", provides key ... The report provides value, in millions of US dollars, ... segements - Phacoemulsification Equipment and Ophthalmic Viscoelastic Devices (OVD). ... shares data for each of these market segements, and ...
(Date:1/19/2017)... -- The U.S. Food and Drug Administration today approved Trulance ... adult patients. "No one medication works for ... Beitz , M.D., director of the Office of Drug Evaluation ... "With the availability of new therapies, patients and their doctors ... ...
(Date:1/19/2017)... Jan. 19, 2017 Many patients don,t realize ... medication when a pharmacy just a few blocks away ... alleviate this problem Medicationdiscountcard.com has created a ... exactly how much their medication will cost at most ... Medicationdiscountcard.com takes all ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than ... the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” ... career as an educator interacting with countless women who had little knowledge of the ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R Burton Healthcare ... device, was featured in a study indicating superior performance against competitive products in ... of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and ... the issue of world hunger, and shares the simple and achievable answer. “The Land ... and member of the Fairview Missionary Church in Angola, Indiana where he works with ...
(Date:1/19/2017)... ... 2017 , ... Next week after January 20th, the fear for many is ... circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis at ... public servants were suppose to prioritize. Interviews provided below. , Among those ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... for tech innovators, engineers, and scientists from around the world, announces the launch ... users a quick and easy portal to research breakthroughs and trending news, vital ...
Breaking Medicine News(10 mins):